Formulation and Evaluation of Favipiravir Proliposomal Powder for Pulmonary Delivery by Nebulization

Naseeb Basha Shaik , Lakshmi PK , Basava Rao VV

Abstract

The favipiravir proliposomal is a powder formulation for pulmonary delivery by nebulization, prepared and characterized by film deposition on carrier method. The formulations have good flow properties and upon hydration, liposome vesicles were seen within 2-3 minutes. According to the results of SEM studies the surface morphology was coarse and non-porous. The DSC and XRD studies confirm that the favipiravir drug is crystalline, whereas the FPL6 is amorphous. In-vitro nebulization studies performed using a twin stage impinger (TSI) revealed that the nebulization time ranges from 12.95 to 14.3 minutes. The aerosol mass output and rate ranges from 44.31 to 54.28 %, and 0.17 to 0.22 mg/min. respectively. The respirable fraction ranges from 8.14 to 12.31%. The FPL6 formulation has a higher respirable fraction of 12.31%, which is available for therapeutic action in the lungs and stable. The results showed that the favipiravir proliposomal formulation was suitable for pulmonary drug delivery via nebulization.


How to cite:
Vancouver
Shaik NB, PK L, VV BR. Formulation and Evaluation of Favipiravir Proliposomal Powder for Pulmonary Delivery by Nebulization. Int J Pharm Res Allied Sci. 2022;11(2):36-44. https://doi.org/10.51847/4McfhPccXs
APA
Shaik, N. B., PK, L., & VV, B. R. (2022). Formulation and Evaluation of Favipiravir Proliposomal Powder for Pulmonary Delivery by Nebulization. International Journal Of Pharmaceutical Research And Allied Sciences, 11(2),36-44. https://doi.org/10.51847/4McfhPccXs